Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Evaluate the Noninferiority of Medicines Treating Uninfected Pressure Ulcers.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02004626
Recruitment Status : Withdrawn
First Posted : December 9, 2013
Last Update Posted : July 16, 2015
Sponsor:
Collaborator:
Newco Trials Pesquisa Científica Ltda
Information provided by (Responsible Party):
Cristália Produtos Químicos Farmacêuticos Ltda.

Brief Summary:

This is a Clinical study Phase III, Prospective, Randomized, Controlled, Double-blind, Multicenter, National, Non-inferiority.

Its purpose is to determine the noninferiority in efficacy of an investigational product in relation to the product available in the market intended of treating pressure ulcers.


Condition or disease Intervention/treatment Phase
Pressure Ulcer Drug: Collagenase Drug: Kollagenase Phase 3

  Hide Detailed Description

Detailed Description:

Objectives:

The primary objective of efficacy is the reduction in the area of devitalized tissue based on the photographic record.

The secondary objective is to evaluate:

  • formation of granulation tissue;
  • the lesion reduction during treatment;
  • the healing process of the Pressure Ulcer (PU) range of PUSH;
  • the safety of the investigational product.

Study Plan:

  • Estimated 92 research participants;
  • Aged between ≥ 18 years and ≤ 80 years - both sexes;
  • Visits from 1 to 10;
  • The maximum lasting period in the study for each research participant will be approximately four weeks.

Evaluations During Study:

Evaluation of Digital Photography: The digital photographic record can provide the relative size of the wound, the tissue color and condition of the surrounding skin. The evaluation of digital photograph of each research participant will be performed by the classification assigned to the decrease of devitalized area and tissue e repair related to the time of healing and observed the formation of granulation tissue and epithelialization from standardized photographs.

Evaluation by PUSH Scales:

In order to provide an evaluation instrument of PUs in Brazil, so that satisfies the simplicity of the use in different clinical scenarios keeping its measurement properties, as previously attested from its original version, the PUSH scale was adapted into Portuguese.

The PUSH Scale considers three parameters or sub - scales of the wound healing process and treatment outcomes: wound area, amount of exudate present on the wound, appearance of the wound.

Retention of Records:

The investigator shall retain all documentation of the study over a period of at least five years from the end of the study. The Sponsor or its designee will provide a list of all documentation which should be kept by the Investigator.

Monitoring:

All aspects of the study will be carefully monitored by Cristália Pharmaceutical Chemicals Ltda. or designated representative of it (Clinical Research Organization - CRO) for evaluations related to good clinical practice and applicable local regulations.

Case Report Forms:

The Monitor will be available if the investigator, or other person of his team, needs information and guidance.

The Monitor of the study should have permanent access to all documentation and it is his obligation to ensure that the Case Report Forms are complete and completed correctly, as well as checking if the data are described according to the source documents, in order to eliminate interferences that may compromise the accuracy of the data generated in the clinical trial.

Audit and Inspections:

Authorized representatives of the Sponsor or designees, regulatory authority or the Ethics Committee of the institution may conduct audits or inspections during or after the study conclusion.

Collecting Data:

The information corresponding to the data of interest from the study will be collected and recorded in Case Report forms provided by Sponsor, and filled from the information contained in the source documents.

Documents are considered sources for study: medical records used by the professional at the time of the visits, diagnostic tests or image.

Informed Consent of Trial:

The Principal Investigator will ensure that the research participant receive verbally and in writing all relevant information about the nature, purpose, the test drug, the possible risks and benefits of the study.

Research participants will be notified that they are free to discontinue the study at any time. That they will have the opportunity to ask questions and to have sufficient time to consider the information received.

Formation of the database:

The database of the study will be assembled with the data from the Case Report Forms. Doubts and discrepancies will generate questions (queries) written to the Principal Investigator.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 0 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: Study Phase III, Randomized, Double-blind, Multicenter, National, to Evaluate the Non-inferiority in Efficacy of Investigational Product Regarding the Comparator Product, in Debridement of Devitalized Tissue in Uninfected Pressure Ulcers.
Study Start Date : January 2015
Estimated Primary Completion Date : June 2015
Estimated Study Completion Date : September 2015

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Pressure Sores

Arm Intervention/treatment
Active Comparator: Collagenase

Each gram of ointment contains :

Collagenase ...0.6 U

Vehicle qs ... 1 g

Presentation:

Topic use. 5 g tube of ointment containing smooth, lump-free , pale white to slightly brown with faint characteristic odor .

Dosage The ointment should have full contact with the entire injured area, and uniformly applied twice a day.

Drug: Collagenase

Conduction of security tests: complete coagulation and glycosylated hemoglobin. Volunteers in childbearing age, with β-HCG (human chorionic gonadotropin) test.

Verification of anthropometric data, clinical evaluation, PU evaluation, randomization and treatment start.

Wash the wound with 0.9 % sterile saline solution; Apply of the investigational product directly in the devitalized tissue (necrotic tissue and Slough).

Cover the wound with sterile gauze and dry transparent film. The procedures for the exchange of bandages must be done every day, twice a day until the total debridement of devitalized tissue.

Photographic records.


Active Comparator: Kollagenase

Each gram of ointment contains :

Collagenase ... 0.6 U

Vehicle qs ... 1 g

Presentation

Topic use. 5 g tube of ointment containing brownish clear, fat and weak characteristic odor.

Dosage The ointment should have full contact with all the injured area, being uniformly applied twice a day.

Drug: Kollagenase

Conduction of security tests: complete coagulation and glycosylated hemoglobin. Volunteers in childbearing age, with β-HCG (human chorionic gonadotropin) test.

Verification of anthropometric data, clinical evaluation, PU evaluation, randomization and treatment start.

Wash the wound with 0.9 % sterile saline solution; Apply of the investigational product directly in the devitalized tissue (necrotic tissue and Slough).

Cover the wound with sterile gauze and dry transparent film. The procedures for the exchange of bandages must be done every day, twice a day until the total debridement of devitalized tissue.

Photographic records.





Primary Outcome Measures :
  1. Devitalized tissue reduction. [ Time Frame: A month. ]
    Percentage of the area reduction of devitalized tissue, surrounding the injury total area and devitalized tissue for each 2D photographic record, with the use of standard metric, using the software IMAGE® J.


Secondary Outcome Measures :
  1. Injury reduction. [ Time Frame: A month. ]
    Evaluation of the wound area, related to the greatest length (in cephalo-caudal direction) versus the greatest width (horizontal line from right to left) in square centimeters, using the software IMAGE® J.

  2. Granulation tissue formation. [ Time Frame: A month. ]
    Classification assigned to the reduction of devitalized area and from tissue repair related to the time for healing and verified by formation of granulation and epithelialization tissue from standardized photographs using the software IMAGE® J.

  3. Healing process of PU. [ Time Frame: A month. ]
    Evolution of the healing process of PU by PUSH Scale.

  4. Adverse events. [ Time Frame: A month. ]
    Frequency and percentage of adverse effects occurrence by the participants of the research.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Both sexes;
  • Aged ≥ 18 years and ≤ 80 years;
  • Patients hospitalized;
  • Patients with leg ulcers in the sacral region with presence of devitalized/ necrotic tissue indicating conservative debridement;
  • Understanding, agreement and signing the Informed Consent Form (IFC), and the Authorization Term for the Image Use for publication of results

Exclusion Criteria:

  • Infected ulcers;
  • Limited ulcers;
  • Ulcers with indication for surgical debridement ;
  • Periostitis ;
  • Obesity II( BMI ≥ 35 ) ;
  • Severe malnutrition ( BMI < 16 )
  • Hemoglobin (HbA1c ) above the upper limit of normal (ULN ) ;
  • Coagulation Factor twice the ULN ;
  • Patients with pulmonary emphysema and / or Chronic Obstructive Pulmonary Disease (COPD) ;
  • Collagen diseases;
  • Psychiatric illnesses;
  • Patients using cytotoxic agents ;
  • Oncology patients under palliative care ;
  • Outpatients ;
  • Signs of limb ischemia ;
  • Urinary incontinence uncontrolled;
  • Fecal incontinence;
  • Diarrhea that in the opinion of the investigator , compromise the process of debridement;
  • Known allergy from the components of the formulas;
  • Pregnancy ;
  • Breastfeeding ;
  • Local and concomitant use of medications and / or products in the lesion: tyrothricin , gramicidin , tetracycline , hexachlorophene , heavy metals ( mercury, silver) , iodine , potassium permanganate , hydrogen peroxide , soap, detergent.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02004626


Locations
Layout table for location information
Brazil
Clínica Dr. Norton Sayeg Ltda
São Paulo, Brazil, 04063-001
Sponsors and Collaborators
Cristália Produtos Químicos Farmacêuticos Ltda.
Newco Trials Pesquisa Científica Ltda
Investigators
Layout table for investigator information
Principal Investigator: Norton Marcos S. Castro, Medic Clínica Dr. Norton Sayeg Ltda

Layout table for additonal information
Responsible Party: Cristália Produtos Químicos Farmacêuticos Ltda.
ClinicalTrials.gov Identifier: NCT02004626     History of Changes
Other Study ID Numbers: CRT071
First Posted: December 9, 2013    Key Record Dates
Last Update Posted: July 16, 2015
Last Verified: July 2015
Keywords provided by Cristália Produtos Químicos Farmacêuticos Ltda.:
Collagenase
Phase III
National
Noninferiority
Double-blind
Multicenter
Prospective.
Additional relevant MeSH terms:
Layout table for MeSH terms
Pressure Ulcer
Ulcer
Pathologic Processes
Skin Ulcer
Skin Diseases